Baker Avenue Asset Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Baker Avenue Asset Management’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,250	Closed	-$120K	–	282
2021 Q2	$120K	Hold	14,250	–	–	0.01%	238
2021 Q1	$149K	Sell	14,250 -6,000	-30%	-$84.4K	0.01%	236
2020 Q4	$343K	Sell	20,250 -16,000	-44%	-$240K	0.02%	190
2020 Q3	$465K	Sell	36,250 -11,000	-23%	-$139K	0.04%	167
2020 Q2	$667K	Sell	47,250 -22,500	-32%	-$284K	0.06%	147
2020 Q1	$641K	Sell	69,750 -21,500	-24%	-$277K	0.08%	112
2019 Q4	$1.36M	Buy	+91,250	New	+$813K	0.1%	128

Other funds holding PRVB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Baker Avenue Asset Management's PRVB Position: Q3 2021 in Review

Baker Avenue Asset Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2021, closing a stake of 14,250 shares — an estimated $120K sold.

Baker Avenue Asset Management first reported a position in PRVB in Q4 2019 and held it in 7 quarters. The position peaked at $1.36M in Q4 2019. 115 funds tracked by Wall St. Rank hold PRVB as of Q3 2021.

Baker Avenue Asset Management reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Baker Avenue Asset Management sold 14,250 Provention Bio, Inc. Common Stock shares in Q3 2021, an estimated $120K.
Baker Avenue Asset Management first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
Baker Avenue Asset Management's Provention Bio, Inc. Common Stock position peaked at $1.36M in Q4 2019.
115 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2021.

Based on Baker Avenue Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.